Raxibacumab

Revision as of 22:16, 23 September 2019 by ClaireLewis (talk | contribs) (Pregnancy Rating)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Monoclonal antibody
  • Dosage Forms: INJ
  • Routes of Administration: IV
  • Common Trade Names: N/A

Adult Dosing

Distributed directly to CDC

Inhalational anthrax treatment

Inhalational anthrax prophylaxis, post-exposure

Pediatric Dosing

Inhalational anthrax treatment

  • <10 kg
    • 80 mg/kg IV x1
  • 10-40 kg
    • 60 mg/kg IV x1
  • >40 kg
    • 40 mg/kg IV x1
  • Premedicate with antihistamine

Inhalational anthrax prophylaxis, post-exposure

  • <10 kg
    • 80 mg/kg IV x1
  • 10-40 kg
    • 60 mg/kg IV x1
  • >40 kg
    • 40 mg/kg IV x1
  • Premedicate with antihistamine

Special Populations

Pregnancy Rating

  • Category B: benefits outweigh risks during pregnancy

Lactation risk

  • Benefits outweigh risks while breast feeding

Renal Dosing

  • Adult: Not defined
  • Pediatric: Not defined

Hepatic Dosing

  • Adult: Not defined
  • Pediatric: Not defined

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Infusion reaction

Common

  • Rash, pruritus
  • Extremity pain

Pharmacology

  • Half-life: 22 days
  • Metabolism: Unknown
  • Excretion: Unknown

Mechanism of Action

  • Binds to anthrax toxin

Comments

See Also

Bioterrorism

References